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Abstract We have previously identified the binding region of a
new Ca2+ antagonist semotiadil in the skeletal muscle Ca2+
channel. To the same semotiadil derivatives, the cardiac
counterpart showed distinct and different binding characteristics :
semotiadil and its photoaffinity analog D51-4700 inhibited
[3H]PN200-110 binding to cardiac membrane preparations with
IC50 values of 13^20 WM, which are 10 times higher than those in
skeletal muscle. Hill slopes of the binding inhibition were 0.94^
1.0 for the cardiac channels compared to 0.63^0.67 for the
skeletal muscle channels. A possible explanation for the
difference is that the semotiadil binding site is differently
conferred in cardiac and skeletal muscle Ca2+ channels. To
reveal this within the primary structure, photoaffinity labeling of
cardiac membranes was employed. [3H]D51-4700 was photo-
incorporated in several polypeptides but only the K1 subunit of
the Ca2+ channel was photolabeled in a specific manner.
Antibody mapping of the [3H]D51-4700-labeled K1 subunit with
several anti-peptide antibodies revealed that the labeled site was
located solely in a peptide fragment between Cys1461 and Lys1529.
This region encompasses the labeled site of skeletal muscle, but
contains several non-identical amino acid residues, which may
participate in expressing different binding characteristics be-
tween the two muscle type Ca2+ channels.
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1. Introduction
Ca2 antagonists bind to L-type Ca2 channels and block
the entry of extracellular Ca2. Three classes of Ca2 antag-
onists, 1,4-dihydropyridines (DHP), phenylalkylamines (PAA)
and benzothiazepines (BTZ), bind to di¡erent regions on the
K1 subunit of Ca2 channels [1,2] as shown by photoa⁄nity
labeling and molecular biological studies. As to the DHP
binding site, not only transmembrane segment IVS6 but also
IIIS6 and IIIS5 have been identi¢ed as molecular determi-
nants of binding [3^8]. This is consistent with photolabeling
results [9,10]. With regard to the PAA site, photolabeling
studies identi¢ed IVS6 as the binding site [11]. Molecular mu-
tagenesis studies showed that IIIS6 is a molecular determinant
of high a⁄nity binding [12^14]. With regard to the BTZ site,
IVS6 [15] and the connecting loop between IVS5 and IVS6
[16] are constituents of the binding site. Taken together, IVS6
must represent a common and important region, although not
su⁄cient, for the binding site of the three classes of Ca2
antagonists. These results can also explain the well-known
allosteric interactions with one another [17].
Semotiadil, a new Ca2 antagonist with the 1,4-benzothia-
zine ring structure, shows di¡erent pharmacological actions
than the conventional drugs. For example, semotiadil is lon-
ger-lasting than diltiazem and nifedipine [18,19]. In addition,
semotiadil shows a higher selectivity for blood vessels com-
pared with cardiac tissues than diltiazem but a lower selectiv-
ity than nifedipine [18,19]. Semotiadil has a negative allosteric
interaction with DHP, PAA and BTZ in skeletal muscle Ca2
channels [20^22] but equivalent data are not available for the
cardiac Ca2 channels. Therefore, localization of the semotia-
dil binding site is an interesting and potentially important
subject. Initially we reported photoa⁄nity labeling of skeletal
muscle Ca2 channels using [3H]D51-4700, a photoa⁄nity
analog of semotiadil. This reagent labeled a region that over-
lapped with but was not identical to those for the conven-
tional drugs [23]. When semotiadil and D51-4700 were applied
to the cardiac Ca2 channels, their binding characteristics
were distinct from the skeletal muscle counterpart, suggesting
that the semotiadil binding site is conferred di¡erently be-
tween the two L-type channels. In order to reveal this within
the primary structure, we employed photoa⁄nity labeling of
the cardiac Ca2 channels with [3H]D51-4700. In this paper,
we describe the localization of the photolabeled site of the
cardiac Ca2 channels and compare the semotiadil binding
site for the cardiac Ca2 channels with the skeletal muscle
counterpart.
2. Materials and methods
2.1. Materials
[3H]D51-4700 (77.6 Ci/mmol) was synthesized as described [24].
Semotiadil was obtained from Daiichi Pharmaceutical Co., Ltd. En-
zymes and chemicals were obtained from the following sources: Ach-
romobacter lyticus protease I (Lys-C) and digitonin from Wako Pure
Chemicals (Osaka, Japan); protein A-Sepharose CL-4B and WGA-
Sepharose 4B from Pharmacia Biotech Inc.; [3H](+)PN200-110 (83.0
Ci/mmol) from NEN; prestained molecular weight standard-low from
Life Technologies, Inc.; unstained high molecular weight standard
from Bio-Rad; scintillation cocktail ACS II from Amersham; dimeth-
yl pimelimidate from Pierce.
2.2. Anti-peptide antibodies
Polyclonal antibodies, raised against synthetic peptides correspond-
ing to particular regions of rabbit skeletal muscle K1 subunit sequence
[25], were used. We con¢rmed that the corresponding amino acid
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sequences were almost identical to those of porcine cardiac muscles by
RT-PCR experiments. The peptides of the skeletal muscle channels we
used and their corresponding sequence to the cardiac channels are as
follows: P9, skeletal 1382^1400 for cardiac 1507^1525 with no se-
quence di¡erence; P0, skeletal 1401^1414 for cardiac 1526^1539
with one substitution of A for R at the 1404 position; P7, skeletal
1011^1026 for cardiac 1142^1157 with two substitutions of Q for E
and A for S at the 1018 and 1023 positions, respectively. Sequences of
the three cardiac peptides from porcine hearts were totally identical to
those [26] from rabbit hearts. Methods for raising antibodies have
been described previously [23,9].
2.3. Preparation of immunoa⁄nity beads of monoclonal antibody
Monoclonal antibody was puri¢ed from ascites by the usual meth-
od using protein A-Sepharose. The ascites were produced by injection
of hybridoma 7H7 which was a gift from Dr. M. Takahashi (Mitsu-
bishi Kasei Institute of Life Sciences). The hybridoma 7H7 produces
monoclonal antibody against the fusion protein containing a 549 ami-
no acid coding region of the C-terminus in the K1 subunit of the
cardiac Ca2 channel; the preparation of the fusion protein has
been described in the literature [27]. A⁄-Gel 10 was used to immobi-
lize the puri¢ed IgG.
2.4. Binding assays
The inhibition assay of semotiadil and D51-4700 to the
[3H](+)PN200-110 binding to the Ca2 channel preparations was per-
formed essentially as described by Nakayama et al. [21] with some
modi¢cations. Brie£y, sarcolemmal-rich membranes from porcine
hearts (40 Wg protein, 0.04 pmol of [3H](+)PN200-110 binding sites;
0.04 nM) were incubated with 0.3 nM of [3H](+)PN200-110 in the
dark for 40 min at 37‡C in assay bu¡er (50 mM Tris-HCl (pH 7.4), 2
mM CaCl2, 0.1 mM PMSF) in the presence or absence of varying
concentrations of semotiadil and D51-4700. For the assay of triad
membranes (5 Wg protein, 0.1 pmol of [3H](+)PN200-110 binding
sites; 0.1 nM) which was prepared from rabbit skeletal muscle as
described by Mitchell et al. [32], 2 nM of [3H](+)PN200-110 was
used. In order to obtain accurate IC50 values, the [3H](+)PN200-110
concentrations used above were around Kd values for the two Ca2
channels and were kept in excess over the receptor concentrations.
Membrane-bound radioactivity was determined by a rapid ¢ltration.
All assay were performed in triplicate. The data were analyzed with a
non-linear least squares LIGAND program originally described by
Munson and Rodbard [33].
2.5. Photoa⁄nity labeling and puri¢cation of K1 subunit of porcine
cardiac Ca2+ channel
Sarcolemmal-rich membranes were isolated from porcine hearts as
described previously [28]. The membranes (80^100 pmol of [3H](+)-
PN200-110 binding sites, 80 mg of proteins) were incubated with 200
nM [3H]D51-4700 in 20 ml of binding bu¡er (25 mM Tris-HCl (pH
7.4), 0.1 mM PMSF, 1 Wg/ml pepstatin A, 1 Wg/ml leupeptin, 10 Wg/ml
soybean trypsin inhibitor and 0.5 mM iodoacetamide) in the presence
or absence of 10 WM semotiadil at 30‡C for 60 min. The incubation
mixture was transferred into a glass Petri dish on ice, and irradiated
for 20 min with a 100 W black light/blue lamp (Ultra-Violet Products,
San Gabriel, CA) at a distance of 10 cm. After photolysis, [3H]D51-
4700-labeled Ca2 channels were solubilized in 1% (w/v) digitonin and
puri¢ed by a⁄nity chromatography on WGA-Sepharose 4B according
to the described method [28]. After solubilization, all the subsequent
procedures were performed at 4‡C and all the bu¡er contained ¢ve
protease inhibitors (0.1 mM PMSF, 1 Wg/ml pepstatin A, 1 Wg/ml
leupeptin, 10 Wg/ml soybean trypsin inhibitor and 0.5 mM iodoaceta-
mide). The eluate from WGA-Sepharose 4B was then puri¢ed by
immunoa⁄nity chromatography. This step was essential to isolate
the Ca2 channel. The WGA-Sepharose eluate was loaded on a
7H7-agarose. The gel was washed with bu¡er (20 mM Tris-HCl
(pH 7.4), 1 mM CaCl2, 0.2M NaCl, 0.1% digitonin) and eluted with
elution bu¡er (0.1 M glycine-HCl (pH 3.0), 0.2 M NaCl, 0.1% digi-
tonin). The eluate was immediately adjusted to pH 7.4 by addition of
1 M Tris-HCl (pH 9.0). Peak fractions were pooled and dialyzed
against 2 mM Tris-HCl (pH 7.4) followed by lyophilization. The
photolabeled and puri¢ed protein was then subjected to carboxyme-
thylation and photolabeled K1 subunits were further puri¢ed by gel
permeation liquid chromatography as described [23]. Fractions corre-
sponding to the K1 subunit were pooled, lyophilized and stored at
330‡C until use.
2.6. Proteolytic of [3H]D51-4700-labeled K1 subunit
The photolabeled K1 subunit was dissolved in deionized water (0.5
ml) and dialyzed against 6 M urea as described [9], followed by dial-
ysis against 0.01% Triton X-100 for 6 h. The sample was digested with
Lys-C (100 Wg/ml) in 50 mM Tris-HCl (pH 9.0) containing 0.05% (w/
v) SDS and 0.01% (v/v) Triton X-100 (¢nal volume of 100 Wl) at 37‡C
for 6 h.
2.7. Immunoprecipitation
Antibodies were bound to protein A-Sepharose CL-4B gel by in-
cubating 1 volume of antiserum with 1 volume of the swollen gel in
the bu¡er A (10 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.1% (v/v)
Triton X-100 and 1 mg/ml bovine serum albumin) for 2 h at 4‡C. The
gel was washed with ice-cold bu¡er A before addition of digested or
non-digested [3H]D51-4700-labeled K1 subunits. After incubation for
2 h at room temperature, the gel was washed with bu¡er A. Immuno-
precipitated radioactivity was directly determined by liquid scintilla-
tion counting of the protein A-Sepharose CL-4B gel with 100 mM
sodium citrate (pH 3.0). Immunoprecipitated labeled fragments were
extracted from the gel with a sampling bu¡er for SDS-PAGE (50 mM
Tris-HCl (pH 6.8), 4% (w/v) SDS, 2% (v/v) 2-mercaptoethanol and
12% (v/v) glycerol) for 3 min at 90‡C and analyzed by SDS-PAGE.
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Fig. 1. Inhibition of [3H](+)PN200-110 binding to the Ca2 channel
preparations by semotiadil and its photoa⁄nity analog. Porcine car-
diac sarcolemmal-rich membranes (A) and rabbit skeletal triad
membranes (B) were used. Semotiadil (a) and D51-4700 (b) are the
tested drugs and unlabeled ( þ )PN200-110 (O) is used as control.
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To determine the size of immunoprecipitated fragments, the antibody-
protein A Sepharose complex was crosslinked with dimethyl pimeli-
midate as described by Schneider et al. [29].
2.8. SDS-PAGE and radioluminography
Intact K1 subunits were analyzed on SDS-PAGE using a 8% poly-
acrylamide gel according to Laemmli [30] and a sampling bu¡er (10
mM Tris-HCl (pH 7.6), 1% (w/v) SDS, 20 mM dithiothreitol, 4 mM
ethylenediaminetetraacetic acid and 2% (w/v) sucrose). For separation
of proteolytic fragments, the gel system described by Schaºgger and
von Jagow [31] (4% stacking gel, 10% spacer gel and 16.5% separating
gel, 3 or 6% cross-linking) was used. For visualization of the tritiated
proteins and peptides, a more sensitive method (‘radioluminography’)
than £uorography was used as previously described [23].
3. Results
3.1. Binding
Fig. 1 shows the e¡ects of semotiadil and its photoa⁄nity
analog D51-4700 on the binding of [3H](+)PN200-110 to the
porcine cardiac and rabbit skeletal muscle membrane prepa-
rations. Both compounds inhibited the [3H](+)PN200-110
binding but dose dependences were di¡erent between the car-
diac and skeletal muscle preparations. IC50 values of semotia-
dil and D51-4700 to the cardiac muscle membranes were 20
WM and 13 WM, respectively, while those to the skeletal
muscle membranes were 2.0 and 1.5 WM. The data show
that the inhibitions of semotiadil analogs to the cardiac mem-
branes are approximately 10 times less e¡ective than those to
the skeletal muscle membranes.
With regard to the Hill slope, 1.0 and 0.97 were obtained
for semotiadil and D51-4700 in the cardiac membranes, re-
spectively, and 0.63 and 0.67 in the skeletal muscle mem-
branes, suggesting no apparent allosteric interactions exist be-
tween the semotiadil analogs and PN200-110 in the cardiac
membranes but negative allosteric interactions operate in the
skeletal muscle membranes. The IC50 (2.0 WM) and Hill slope
(0.63) of semotiadil for the skeletal membranes are close to
the reported values in canine skeletal membranes (5.4 WM and
0.57, respectively) [21,22]. As reference, ( þ )PN200-110 inhib-
ition in the cardiac and skeletal muscle membranes is shown
in Fig. 1, where Hill slopes were 1.0 and 0.97, and IC50 were
0.4 nM and 2.0 nM, respectively, values which are consistent
with previous observations [21,34].
3.2. Photolabeling
[3H]D51-4700 photolabeled several polypeptides in the por-
cine cardiac membranes (Fig. 2, lane 1). However, only the K1
subunit-bound label (180 kDa) of the Ca2 channel was se-
lectively inhibited in the presence of excess semotiadil (lane 2).
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Fig. 2. Photolabeling of cardiac Ca2 channel preparations with
[3H]D51-4700. Sarcolemmal-rich membranes from porcine hearts
were photolabeled with 200 nM [3H]D51-4700 in the absence (lane
1) or presence (lane 2) of 10 WM semotiadil. Both samples were
then solubilized and puri¢ed to give the puri¢ed samples that were
photolabeled in the absence (lane 3) or presence (lane 4) of 10 WM
semotiadil. All the samples were analyzed on SDS-PAGE followed
by radioluminography. The migration of the K1 subunit and of mo-
lecular mass markers (shown in kDa) is indicated.
Fig. 3. Analysis of Lys-C digests of photolabeled K1 subunit by
SDS-PAGE and immunoprecipitation. A: SDS-PAGE analysis of
Lys-C digests of photolabeled K1. [3H]D51-4700-labeled K1 was di-
gested with Lys-C and an aliquot was separated on a Schaºgger and
von Jagow gel (lane 1). Another aliquot was subjected to immuno-
precipitation with anti-P9 antibody and the immunoprecipitated
fragments were analyzed on the same gel system (lane 2). The pho-
tolabeled band was visualized by radioluminography. The migration
of prestained molecular mass markers (given in kDa) is indicated.
B: Immunoprecipitation of [3H]D51-4700-labeled peptide fragment
from Lys-C digests. Photolabeled K1 subunits were digested in the
absence (open bars) or presence (¢lled bars) of Lys-C. Both samples
were probed in parallel with the anti-peptide antibodies. The immu-
noprecipitated percentages are shown and the immunoprecipitated
dpms normalized with respect to the dpms immunoprecipitated in
non-digested samples (100%) are shown as hatched bars.
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Selective labeling was also con¢rmed when the photolabeled
cardiac membrane preparation was solubilized by digitonin
and a⁄nity-puri¢ed by WGA-Sepharose and antibody col-
umn. In the puri¢ed sample, a single band of 180 kDa was
photolabeled (lane 3) while the labeled band was not observed
when photolabeling was done in the presence of excess sem-
otiadil (lane 4).
3.3. Localization
To determine the localization of the photolabeled site with-
in the K1 subunit, we subjected the photolabeled K1 subunit to
protease digestion with an endoprotease Lys-C and probed
the Lys-C fragment by immunoprecipitation with a series of
sequence-directed antibodies (see Section 2) against di¡erent
regions of K1. The Lys-C digestion of K1 is shown in Fig. 3,
resulting in labeled fragments of 8.9 kDa predominantly and
12.4 kDa as a minor product (Fig. 3A, lane 1).
In immunoprecipitation, all three antibodies reacted with
cardiac non-digested K1 subunit at 40^45% (Fig. 3B), indicat-
ing that the anti-peptide antibodies that were raised against
the peptide sequence of rabbit skeletal muscle channels have
almost equal potencies to crossreact with the corresponding
porcine cardiac channel peptides, even though two peptides
(P0 and P7) have one or two di¡erent amino acid substitu-
tions. In contrast, immunoprecipitation after Lys-C digestion
with the same antibodies revealed that only the anti-P9 anti-
body directed against sequence 1507^1525 immunoprecipi-
tated the photolabeled fragments while anti-P0 and anti-P7
antibodies did not immunoprecipitate at all (Fig. 3B).
It is of note that about 51% of the K1-associated labeling
was associated with the fragment recognized by the anti-1507^
1525 antibody, because the immunoprecipitated percentage
was calculated as 121% when the radioactivity of the immu-
noprecipitated fragment was normalized with respect to that
in non-digested samples (100%) (Fig. 3B). Similar result have
been reported in the photolabeling of skeletal muscle channels
with [3H]D51-4700 [23]. This is probably due to the fact that
higher reactivity of the anti-peptide antibodies occurs to the
peptide fragments than to the non-digested polypeptide K1.
Therefore, applied radioactivity was recognized quantitatively
by the anti-1507^1525 antibody, strongly suggesting that the
labeled site is located solely in a fragment of the 8.9 kDa
band. The latter was con¢rmed by SDS-PAGE analysis of
the antibody-bound radioactivity (Fig. 3A, lane 2).
4. Discussion
Binding studies of semotiadil to Ca2 channels in skeletal
muscle have been reported [20^22], but no data are available
for cardiac preparations. We ¢rst tried saturation binding,
using varying concentrations of tritiated analogs of semotiadil
and D51-4700 to cardiac membranes, but the level of non-
speci¢c binding was too high for analysis. However, inhibition
assays of semotiadil and D51-4700 for [3H](+)PN200-110
binding to cardiac membrane preparations were successfully
carried out and analyzed. Hill slopes of the binding inhibition
were 0.94^1.0 in cardiac channels, indicating no apparent al-
losteric interaction between PN200-110 (isradipine) and sem-
otiadil. This is in clear contrast to observations in the skeletal
channel [20^22], in which semotiadil has a negative allosteric
interaction with DHP, PAA and BTZ. The negative allosteric
interaction was con¢rmed in the present work and the Hill
slopes obtained were 0.63^0.67, similar to a previous report
[21]. In addition, IC50 values for binding inhibition of semo-
tiadil and its analog to the cardiac Ca2 channel were 10 times
higher than those for skeletal muscle. These results suggest
that the semotiadil binding region is di¡erently con¢gured in
the Ca2 channels from heart and skeletal muscle.
Photoa⁄nity labeling and location of the labeled site were
employed in determining structural requirements for the dif-
ferent binding in the cardiac channel. The photolabeled site of
the cardiac Ca2 channel was located to the single Lys-C-
digested peptide fragment of Cys1461^Lys1529 (8.9 kDa), as
shown in Fig. 4. The peptide was similar to the photolabeled
and Lys-C-digested fragment (8.3 kDa) in skeletal muscle
Ca2 channel (Fig. 4) which we previously reported [23]. As
far as we know of Ca2 antagonists, this is the ¢rst example
that photolabeled sites are identi¢ed in two types of L-type
Ca2 channels from di¡erent tissues. The present data suggest
that the semotiadil binding site is con¢gured with the homol-
ogous segment containing transmembrane IVS6 and adjacent
extracellular and/or intracellular stretches in both Ca2 chan-
nels. However, it must be noted that the sequences are not
identical.
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Fig. 4. Comparison of labeled fragment location in the cardiac and skeltal muscle Ca2 channels. Amino acid sequences of the porcine cardiac
peptide fragment (8.9 kDa) which is located as [3H]D51-4700-labeled site is shown by comparison with the corresponding fragment in the rab-
bit skeltal muscle counterpart (8.3 kDa) and its smallest labeled region (1350^1381) identi¢ed previously [23]. The sequence of the cardiac pep-
tide (1460^1540) from porcine heart was con¢rmed to be identical to that from rabbit heart [26] by RT-PCR. Therefore, between two sequneces
of the cardiac and skeletal channels, identical and non-identical amino acids are shown in dark and light bold, respectively. A schematic align-
ment of the transmembrane segment S6 (shadowed) in repeat IV and antibodies (P9 and P0) used is also indicated at the bottom.
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The results, taken together, permit us to speculate on the
labeling and binding sites as follows. Within the 8.9 kDa frag-
ment, the most probable labeled site is the peptide between
Thr1475 and Met1507 which is the corresponding peptide
(Tyr1350^Met1381) identi¢ed in the skeletal muscle counterpart
[23]. There are six di¡erent amino acids in the N-terminal
portion. If this is the case, the binding sites for the two chan-
nels may consist of the same local segment but di¡erent amino
acid residues are probably involved in the expression of the
di¡erent binding characteristics of semotiadil and its photo-
a⁄nity analog. The adjacent N-terminal extracellular stretch
is another candidate for the labeled site since the sequences
are di¡erent between the two channels except for two amino
acids, Gly-Glu. In this context, it is less probable that the
labeled site exists in the intracellular stretch because the ami-
no acid sequence Asp1507^Lys1529 in the cardiac fragment is
identical to the skeletal muscle sequence except for Phe1528.
Alternatively, it is possible that the binding site is composed
of several segments and the identi¢ed region by photoa⁄nity
labeling is only a component of the entire binding site. PAA is
such an example in which photolabeling occurred in the single
peptide containing segment IVS6 with the adjacent extracel-
lular and intracellular stretches [11]. Subsequent site-directed
mutagenesis showed that not only IVS6 [12,13] but also IIIS6
appears to determine high a⁄nity binding of a PAA analog
[14].
This is the ¢rst example of di¡erential binding sites for a
particular Ca2 antagonist in two L-type Ca2 channels. Fur-
ther molecular biological studies are necessary to clarify the
semotiadil binding site including whether additional seg-
ment(s) is/are required to form the pocket for cardiac and
skeletal muscle Ca2 channels.
Acknowledgements: We thank Dr. Masami Takahashi, Mitsubishi
Kasei Institute of Life Sciences, for the generous gift of hybridoma
7H7. This work was supported in parts by Grants-in Aid for scienti¢c
research on priority areas of ‘Channel-Transporter Correlation’ Nos.
08268241 and 09257237, and ‘Biological Functions and Designed
Probe Compounds’ No. 09273102, and general subject Nos.
A08557138 and B09470513 from the Ministry of Education, Science,
Sports and Culture of Japan (to H.N.) and PO1 HL 22,619 from the
NIH (A.S.).
References
[1] Varadi, G., Mori, Y., Mikala, G. and Schwartz, A. (1995) Trends
Pharmacol. Sci. 16, 43^49.
[2] Nakayama, H. and Kuniyasu, A. (1996) Jpn. Heart J. 37, 643^
650.
[3] Tang, S., Yatani, A., Bahinski, A., Mori, Y. and Schwartz, A.
(1993) Neuron 11, 1013^1021.
[4] Peterson, B.Z., Tanada, T.N. and Catterall, W.A. (1996) J. Biol.
Chem. 271, 5293^5296.
[5] Grabner, M., Wang, Z., Hering, S., Striessnig, J. and Glossmann,
H. (1996) Neuron 16, 207^218.
[6] Schuster, A., Lacinova, L., Klugbauer, N., Ito, H., Birnbaumer,
L. and Ho¡man, F. (1996) EMBO J. 15, 2365^2370.
[7] Mitterdorfer, J., Wang, Z., Sinnegar, M.J., Hering, S., Striessnig,
J., Grabner, M. and Glossmann, H. (1996) J. Biol. Chem. 271,
30330^30335.
[8] He, M., Bodi, I., Mikkala, G. and Schwartz, A. (1997) J. Biol.
Chem. 272, 2629^2633.
[9] Nakayama, H., Taki, M., Striessnig, J., Glossmann, H., Catter-
all, W.A. and Kanaoka, Y. (1991) Proc. Natl. Acad. Sci. USA
88, 9203^9207.
[10] Striessnig, J., Murphy, B.J. and Catterall, W.A. (1991) Proc.
Natl. Acad. Sci. USA 88, 10769^10773.
[11] Striessnig, J., Glossmann, H. and Catterall, W.A. (1990) Proc.
Natl. Acad. Sci. USA 87, 9108^9112.
[12] Hockerman, G.H., Johnson, B.D., Sheuer, T. and Catterall,
W.A. (1995) J. Biol. Chem. 270, 22119^22122.
[13] Doering, F., Degitar, V.E., Grabner, M., Striessnig, J., Hering,
S. and Glossmann, H. (1996) J. Biol. Chem. 271, 11745^
11749.
[14] Hockerman, G.H., Johnson, B.D., Abbott, M.R., Sheuer, T. and
Catterall, W.A. (1997) J. Biol. Chem. 272, 18759^18765.
[15] Hering, S., Axzel, S., Grabner, M., Doering, F., Berjukow, S.,
Mitterdorfer, J., Sinnegar, M.J., Striessnig, J., Degitar, V.E.,
Wang, Z. and Glossmann, H. (1996) J. Biol. Chem. 271,
24471^24475.
[16] Watanabe, T., Kalasz, H., Yabana, H., Kuniyasu, A., Mershon,
J., Itagaki, K., Vaghy, P.L., Naito, K., Nakayama, H. and
Schwartz, A. (1993) FEBS Lett. 334, 261^264.
[17] Glossmann, H. and Striessnig, J. (1990) Rev. Physiol. Biochem.
Pharmacol. 114, 1^105.
[18] Miyazaki, N., Furuta, T., Shigei, T., Yamauchi, H. and Iso, T.
(1991) Life Sci. 48, 1903^1909.
[19] Mori, T., Ishigai, Y., Fukuzawa, A., Chiba, K. and Shibano, T.
(1995) Br. J. Pharmacol. 116, 1668^1672.
[20] Nakayama, K., Morimoto, K., Nozawa, Y. and Tanaka, Y.
(1992) J. Cardiovasc. Pharmacol. 20, 380^391.
[21] Nakayama, K., Nozawa, Y. and Fukuta, Y. (1994) J. Cardio-
vasc. Pharmacol. 23, 731^740.
[22] Nakayama, K. (1996) Cardiovasc. Drug Rev. 14, 97^134.
[23] Kuniyasu, A., Itagaki, K., Shibano, T., Iino, M., Kraft, G.,
Schwartz, A. and Nakayama, H. (1998) J. Biol. Chem. 273,
4635^4641.
[24] Watanabe, Y., Osanai, K., Nishi, T., Miyawaki, N., Shii, D.,
Honda, T. and Shibano, T. (1996) Bioorg. Med. Chem. Lett. 6,
1923^1926.
[25] Tanabe, T., Takeshima, H., Mikami, A., Flockerzi, V., Takaha-
shi, H., Kangawa, K., Kojima, M., Matsuo, H., Hirose, T. and
Numa, S. (1987) Nature 328, 313^318.
[26] Mikami, A., Imoto, K., Tanabe, T., Niidome, T., Mori, Y.,
Takeshima, H., Narumiya, S. and Numa, S. (1989) Nature 340,
231^233.
[27] Yoshida, A., Takahashi, M., Nishimura, S., Takeshima, H. and
Kokubun, S. (1992) FEBS Lett. 309, 343^349.
[28] Kuniyasu, A., Oka, K., Ide-Yamada, T., Hatanaka, Y., Abe, T.,
Nakayama, H. and Kanaoka, Y. (1992) J. Biochem. 112, 235^
242.
[29] Schneider, C., Newman, R.A., Sutherland, D.R., Asser, U. and
Greaves, M. (1982) J. Biol. Chem. 257, 10766^10769.
[30] Laemmli, U.K. (1970) Nature 227, 680^685.
[31] Schaºgger, H. and von Jagow, G. (1987) Anal. Biochem. 166, 368^
379.
[32] Mitchell, R.D., Palade, P. and Fleisher, S. (1983) J. Cell. Biol. 96,
1008^1016.
[33] Munson, P.J. and Rodbard, D. (1980) Anal. Biochem. 107, 220^
239.
[34] Glossmann, H. and Ferry, D.R. (1985) Methods Enzymol. 109,
513^550.
FEBS 21285 14-12-98
N. Ii et al./FEBS Letters 441 (1998) 83^87 87
